arrow
M

M. Peter Marinkovich

Stanford University
H指数:60
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial

Prademagene zamikeracel 用于隐性营养不良型大疱性表皮松解症伤口的治疗(VIITAL):一项两中心、随机、开放标签、患者内对照的III期临床试验

2025-06-230
PRE
Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa

更正:Beremagene Geperpavec-svdt (B-VEC) 在营养不良性大疱性表皮松解症患者的开放标签扩展研究中的长期安全性与耐受性

2025-06-040
OA
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa

贝雷玛基因·格佩尔帕韦西-svdt(B-VEC)在营养不良性大疱性表皮松解症患者开放标签扩展研究中的长期安全性与耐受性

2025-04-120
OA
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa

基因校正的自体角质形成细胞移植治疗隐性营养不良性大疱性表皮松解症的长期安全性和有效性

2022-10-1719
OAAI
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study
2021-04-0139
OAAI
Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts
2020-10-019
OAAI